Join the Tardive Dyskinesia group to help and get support from people like you.
Tardive Dyskinesia News
Related terms: Tardive, Dyskinesia
Disruptions in Amino Acid, Lipid Metabolism May Signal Tardive Dyskinesia
THURSDAY, March 20, 2025 – Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online Feb. 21 in Schizophrenia Bulletin....
Antipsychotics at Doses >75 mg a Day Linked to Risk for Tardive Dyskinesia
FRIDAY, Jan. 17, 2025 – Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study recently published in the Journal of Clinical...
Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia
MONDAY, Nov. 18, 2024 – Transcranial direct current stimulation (tDCS) may be an effective and safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia (TD) in chronically...
Study Reveals No Link Between HDL Cholesterol and Movement Disorders
FRIDAY, Sept. 20, 2024 – There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient's risk for developing movement disorders while taking an antipsychotic, a...
Alterations in T Cell Subpopulations Linked to Brain Structure in Tardive Dyskinesia
THURSDAY, July 25, 2024 – Alterations in the proportion of T cell subpopulations are associated with brain structural abnormalities in patents with schizophrenia with tardive dyskinesia (TD),...
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
TUESDAY, June 25, 2024 – For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not...
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
TUESDAY, June 25, 2024 – For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not...
Teva Announces Austedo XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE) May 29, 2024 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. ...
Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved Ingrezza Sprinkle (valbenazine) capsules, a...
Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo
New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD)...
Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults
JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo...
FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine)...
Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
SAN DIEGO, April 11, 2017 /PRNewswire/ – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for...